Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer

Inclusion Criteria: * Histologically or cytologically documented pancreatic adenocarcinoma * Clinical T3 or T4 tumor according to AJCC staging system * Tumors considered as borderline resectable or unresectable disease assessed by multidisciplinary team including pancreatic surgeon, gastroenterologist specializing in pancreas, medical oncologist, and radiation oncologist * Age 18 years or older * ECOG performance status 2 or less * Adequate organ function * Adequate bone marrow function (WBCs\> 3,500/µL, absolute neutrophil count \[ANC\]\> 1,500/µL, hemoglobin \> 9.0 g/dL, and platelets \> 100,000/µL) * Adequate kidney function (creatinine \< 1.5 mg/dL) * Adequate liver function (bilirubin \< 1.5 mg/dL \[\<2.5 mg/dL for patients with obstructive jaundice due to pancreatic cancer with adequate decompression\], transaminases levels \< 3 times the upper normal limit) * Patients must not have psychological, familial, sociological or geographical conditions which do not permit medical follow-up and compliance with this study * Women of childbearing potential must have a negative pregnancy test on admission. Post-menopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Men and women of reproductive potential must have agreed to use an effective method of contraception while on treatment and for 6 months after study treatment * The patient must be able to understand the study and has given written informed consent to participate in the study Exclusion Criteria: * Other tumor type than adenocarcinoma * Evidence of gastrointestinal bleeding or obstruction * Presence of the clinically relevant ascites or distant metastases * Past or concurrent history of malignant neoplasm, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri * Pregnant or lactating women, women of childbearing potential not employing adequate contraception * Hypersensitivity to any of the study drugs or ingredients * Other serious illness or medical conditions * Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry * History of significant neurologic or psychiatric disorders including dementia or seizures * Active uncontrolled infection * Pre-existing clinically significant diarrhea * Active peptic ulcer * Severe hypercalcemia of 12 mg/dL uncontrolled with bisphosphonates * Active disseminated intravascular coagulation * Other serious underlying medical conditions which could impair the ability of the patient to participate in the study * Concomitant or administration of any other experimental drug under investigation within 3 weeks before the study * Concomitant chemotherapy, hormonal therapy, or immunotherapy